CADTH Reimbursement Review

Provisional Funding Algorithm

Indication: Chronic Lymphocytic Leukemia

This report supersedes the CADTH Provisional funding algorithm report for chronic lymphocytic leukemia dated October 2023.

Please always check <u>CADTH Provisional Funding Algorithms | CADTH</u> to ensure you are reading the most recent algorithm report.

Service Line: CADTH Reimbursement Review

Version: Draft
Publication Date: Date

9

10 11

12

13

14

Report Length: 12 Pages



Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the *Canadian Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.



Background

Following a request from jurisdictions, CADTH may design or update an algorithm depicting the sequence of funded treatments for a particular tumour type. These algorithms are proposals for the jurisdictions to implement and adapt to the local context. As such, they are termed "provisional." Publishing of provisional algorithms is meant to improve transparency of the oncology drug funding process and promote consistency across jurisdictions.

Provisional funding algorithms are based on 3 principal sources of information:

- CADTH pCODR Expert Review Committee (pERC) reimbursement recommendations and/or implementation guidance regarding drug place in therapy and sequencing
- implementation advice from panels of clinicians convened by CADTH concerning sequencing of drugs in the therapeutic space of interest
- existing oncology drug reimbursement criteria and legacy funding algorithms adopted by jurisdictional drug plans and cancer agencies.

Note that provisional funding algorithms are not treatment algorithms; they are neither meant to detail the full clinical management of each patient nor the provision of each drug regimen. The diagrams may not contain a comprehensive list of all available treatments, and some drugs may not be funded in certain jurisdictions. All drugs are subject to explicit funding criteria, which may also vary between jurisdictions. Readers are invited to refer to the cited sources of information on the CADTH website for more details.

Provisional funding algorithms also delineate treatment sequences available to patients who were never treated for the condition of interest (i.e., incident population). Time-limited funding of new options for previously or currently treated patients (i.e., prevalent population) is not detailed in the algorithm.

Provisional funding algorithms may contain drugs that are under consideration for funding. Algorithms will not be dynamically updated by CADTH following changes to drug funding status. Revisions and updates will occur only upon request by jurisdictions.

Jurisdictional cancer drug programs requested a CADTH provisional funding algorithm on chronic lymphocytic leukemia (CLL). However, no outstanding implementation issues were identified, and no additional implementation advice is provided in this report. The algorithm depicted herein is meant to reflect the current and anticipated funding landscape based on the previously mentioned sources of information.

41

43

45

46

16



History and Development of the Provisional Funding Algorithm

CADTH convened an implementation advice panel and published the first provisional funding algorithm on CLL in May 2021, in order to address various outstanding implementation issues such as the alignment of funding criteria for different treatment options as well as sequencing guidance.

The provisional funding rapid algorithm was then updated in October 2023 to incorporate CADTH recommendation for zanubrutinib for CLL.

This current update in the provisional funding rapid algorithm incorporates the latest CADTH recommendation for ibrutinib (Imbruvica), in combination with venetoclax (Venclexta).

Details of the relevant CADTH recommendations are outlined in Table 1, while Table 2 summarizes conclusions from the Implementation Advice Panel.

Table 1: Relevant CADTH Recommendations

Generic name (brand name)	Date of recommendation	Recommendation and Guidance on Treatment Sequencing
First-Line Setting	•	<u>'</u>
Ibrutinib (Imbruvica) in combination with Venetoclax (Venclexta)	Nov 22, 2023	The CADTH pCODR Expert Review Committee (pERC) recommends that ibrutinib in combination with venetoclax be reimbursed for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL), including those with 17p deletion only if the following conditions are met: 1. Adult (≥ 18 years) patients with previously untreated CLL, including those with 17p deletion. 2. Patients must have a good ECOG performance status. 3. Patients must not have any of the following:



likely be offered the same treatment again as those patients are not necessarily resistant, which could be an advantage over continuous BTK inhibitor treatments. Overall, the clinical expert commented to pERC that a fixed duration treatment (i.e., I+V) might be attractive and used for older on higher-risk patients who have impaired renal function and/or attrial fibrillation, as those patients are more likely to experience adverse events if they have been exposed to BTKis for a long time. • Evidence to support the re-treatment with single-drug librutinib: The clinical expert consulted by CADTH stated that there is no evidence yet. However if patients have a durable response to list treatment (e.g., at least 3 years DOR) then the clinical expert would speculate that re-treatment with brittinib + venetoclax would be considered, pERC akknowledged the clinical expert's recommendation but determined that a 1-year DOR to first treatment would suffice for re-treatment with invulnib + venetoclax whose the considered, pERC also noted that the reassessment of single-drug ibrurinib as re-treatment was beyond the scope of this review. • Intolerance to ibrutinib: The clinical expert consulted by CADTH confirmed that treatment with venetoclax monotherapy should be continued if a patient experiences intolerance to ibrutinib because venetoclax monotherapy is an active therapy in treating patients with CLL. The clinical expert noted that patients receiving venetoclax monotherapy may have an elevated risk of tumour lysis syndrome at the beginning of the treatment. pERC agreed with the clinical expert that administering brutinib in combination with venetoclax would reduce the risk of tumour lysis syndrome in patients with CLL. If patients have to stop ibrutinib due to intolerance, it is safe to continue venetoclax as monotherapy and have not experienced disease progression be elligible for the addition of venetoclax? pERC aspert with the clinical expert consulted by CADTH that several treatments are currently available for first			Guidance on sequencing:
clinical expert consulted by CADTH stated that there is no evidence yet. However if patients have a durable response to first treatment (e.g., at least 3 years DOR) then the clinical expert would speculate that retreatment with ibrutinib + venetoclax would be considered. ¿ERC acknowledged the clinical expert's recommendation but determined that a 1-year DOR to first treatment would suffice for re-treatment with ibrutinib venetoclax to be considered. ¿ERC also noted that the reassessment of single-drug ibrutinib as re-treatment was beyond the scope of this review. • Intolerance to ibrutinib: The clinical expert consulted by CADTH confirmed that treatment with venetoclax monotherapy should be continued if a patient experiences intolerance to ibrutinib because venetoclax monotherapy is an active therapy in treating patients with CLL. The clinical expert noted that patients receiving venetoclax monotherapy may have an elevated risk of tumour lysis syndrome at the beginning of the treatment. ¿ERC agreed with the clinical expert that administering ibrutinib in combination with venetoclax as monotherapy. • Should patients currently receiving ibrutinib monotherapy and have not experienced disease progression be eligible for the addition of venetoclax? ¿ERC cannot comment on this specific enquiry as no data are available. However, ¿ERC asserts that, as a general rule, patients what are already responding to therapy and are not experiencing toxicity should remain on the current therapy without adding a new treatment. pERC agreed with the clinical expert consulted by CADTH that several treatments are currently available for first-line treatment. pERC also noted that use of I+V as a first-line treatment for CLL would impact subsequent treatment sequencing. Further, it is unclear how BTK inhibitors compare to venetoclax-based combination therapies as first-line treatment. Zanubrutinib (Brukinsa) September 20, 2023 CADTH pCODR Expert Review Committee (pERC) recommends that zanubrutinib be reimbursed for the treatment o			cost saving with I+V being a fixed duration and completely oral regimen. According to clinical expert opinion, patients exhibiting good response will likely be offered the same treatment again as those patients are not necessarily resistant, which could be an advantage over continuous BTK inhibitor treatments. Overall, the clinical expert commented to pERC that a fixed duration treatment (i.e., I+V) might be attractive and used for older or higher-risk patients who have impaired renal function and/or atrial fibrillation, as those patients are more likely to experience adverse events
confirmed that treatment with venetoclax monotherapy should be continued if a patient experiences intolerance to ibrutinib because venetoclax monotherapy is an active therapy in treating patients with CLL. The clinical expert noted that patients receiving venetoclax monotherapy may have an elevated risk of tumour lysis syndrome at the beginning of the treatment. pERC agreed with the clinical expert that administering ibrutinib in combination with venetoclax would reduce the risk of tumour lysis syndrome in patients with CLL. If patients have to stop ibrutinib due to intolerance, it is safe to continue venetoclax as monotherapy. • Should patients currently receiving ibrutinib monotherapy and have not experienced disease progression be eligible for the addition of venetoclax? pERC cannot comment on this specific enquiry as no data are available. However, pERC asserts that, as a general rule, patients wh are already responding to therapy and are not experiencing toxicity should remain on the current therapy without adding a new treatment. pERC agreed with the clinical expert consulted by CADTH that several treatments are currently available for first-line treatment, pERC also noted that use of I+V as a first-line treatment for CLL would impact subsequent treatment sequencing. Further, it is unclear how BTK inhibitors compare to venetoclax-based combination therapies as first-line treatment. Zanubrutinib (Brukinsa) September 20, 2023 CADTH pCODR Expert Review Committee (pERC) recommends that zanubrutinib be reimbursed for the treatment of adult patients with chronic lymphocytic leukemia (CLL) only if the following conditions are met: 1. Adult (≥ 18 years) patients with CLL who meet 1 of the following criteria: 1.1. previously untreated CLL for whom fludarabine-based treatment is inappropriate			clinical expert consulted by CADTH stated that there is no evidence yet. However if patients have a durable response to first treatment (e.g., at least 3 years DOR) then the clinical expert would speculate that retreatment with ibrutinib + venetoclax would be considered. pERC acknowledged the clinical expert's recommendation but determined that a 1-year DOR to first treatment would suffice for re-treatment with ibrutinib +
not experienced disease progression be eligible for the addition of venetoclax? pERC cannot comment on this specific enquiry as no data are available. However, pERC asserts that, as a general rule, patients wh are already responding to therapy and are not experiencing toxicity should remain on the current therapy without adding a new treatment. pERC agreed with the clinical expert consulted by CADTH that several treatments are currently available for first-line treatment. pERC also noted that use of I+V as a first-line treatment for CLL would impact subsequent treatment sequencing. Further, it is unclear how BTK inhibitors compare to venetoclax-based combination therapies as first-line treatment. Zanubrutinib (Brukinsa) September 20, 2023 CADTH pCODR Expert Review Committee (pERC) recommends that zanubrutinib be reimbursed for the treatment of adult patients with chronic lymphocytic leukemia (CLL) only if the following conditions are met: 1. Adult (≥ 18 years) patients with CLL who meet 1 of the following criteria: 1.1. previously untreated CLL for whom fludarabine-based treatment is inappropriate			confirmed that treatment with venetoclax monotherapy should be continued if a patient experiences intolerance to ibrutinib because venetoclax monotherapy is an active therapy in treating patients with CLL. The clinical expert noted that patients receiving venetoclax monotherapy may have an elevated risk of tumour lysis syndrome at the beginning of the treatment. pERC agreed with the clinical expert that administering ibrutinib in combination with venetoclax would reduce the risk of tumour lysis syndrome in patients with CLL. If patients have to stop ibrutinib due
treatments are currently available for first-line treatment. pERC also noted that use of I+V as a first-line treatment for CLL would impact subsequent treatment sequencing. Further, it is unclear how BTK inhibitors compare to venetoclax-based combination therapies as first-line treatment. Zanubrutinib (Brukinsa) September 20, 2023 CADTH pCODR Expert Review Committee (pERC) recommends that zanubrutinib be reimbursed for the treatment of adult patients with chronic lymphocytic leukemia (CLL) only if the following conditions are met: 1. Adult (≥ 18 years) patients with CLL who meet 1 of the following criteria: 1.1. previously untreated CLL for whom fludarabine-based treatment is inappropriate			not experienced disease progression be eligible for the addition of venetoclax? pERC cannot comment on this specific enquiry as no data are available. However, pERC asserts that, as a general rule, patients who are already responding to therapy and are not experiencing toxicity should
zanubrutinib be reimbursed for the treatment of adult patients with chronic lymphocytic leukemia (CLL) only if the following conditions are met: 1. Adult (≥ 18 years) patients with CLL who meet 1 of the following criteria: 1.1. previously untreated CLL for whom fludarabine-based treatment is inappropriate			treatments are currently available for first-line treatment. pERC also noted that use of I+V as a first-line treatment for CLL would impact subsequent treatment sequencing. Further, it is unclear how BTK inhibitors compare to
1.1. previously untreated CLL for whom fludarabine-based treatment is inappropriate	Zanubrutinib (Brukinsa)	September 20, 2023	zanubrutinib be reimbursed for the treatment of adult patients with chronic
1.2. relapsed or remitting CLL who have received at least 1 prior systemi therapy.			1.1. previously untreated CLL for whom fludarabine-based treatment is inappropriate1.2. relapsed or remitting CLL who have received at least 1 prior systemic



3. Patients must not have any of the following: 3.1. prior progression on a BTX inhibitor 3.2. prolymphocytic leukemian or Richter's transformation. 4. Renewal of zanubrutinib should be based on the following assessments: 4.1. Blood work and physicial examination should be performed every 1 to 3 months at intitiation there can be performed less frequently (i.e., 3 to 6 months) at the discretion of the treating physician. 5. Treatment with zanubrutinib should be discontinued upon the occurrence of any of the following: 5.1. progression of disease according to iwCLL response assessment criteria 5.2. unacceptable toxicity. 6. Zanubrutinib should only be prescribed by a clinician with expertise and experience in the treatment of CLL and monitoring of therapy. 7. Zanubrutinib should provide cost savings for drug programs relative to the cost of treatment with either intrinsion or acalabrutinib for the treatment of adult patients with CLL. Guidance on sequencing: pERC agreed with the clinical expert consulted by CADTH that selection of a BTK inhibitor as a treatment option will be influenced by differences in patient populations and preferences such as dosing schedule and duration of therapy, side effect profile, and concomitant drug interactions, pErCs anoted the lack of definitive clinical evidence and rationale that favours 1 BTK inhibitor option over another, and thus selection of the BTK inhibitor, would be for the treating clinical not determine in agreement with the patient. pERC agreed with the clinical expert consulted by CADTH obtains who have high-risk features or could not receive by therapy should be able to obtain a BTK inhibitor. Although the clinical expert consulted by CADTH obtain the patients who have high-risk features or could not receive by therapy should not be switched. Venetoclax (Venclexta) in combination with clinical expert noted that patients who are doing well on current treatment (e.g., with brutinib or acalabrutinib) without disease progression should not be switched. Veneto			15000
3.1. prior progression on a BTK inhibitor 3 3.2. prollymphocytic leukemia or Richter's transformation. 4. Renewal of zanubrutinib should be based on the following assessments: 4.1. Blood work and physical examination should be performed every 1 to 3 months at initiation then can be performed every 1 to 3 months at initiation then can be performed every 1 to 3 months at initiation then can be performed every 1 to 3 months at initiation then can be performed every 1 to 3 months at initiation then can be performed every 1 to 3 months at initiation then can be performed eless frequently (i.e., 3 to 6 months) at the discretion of the treating physician. 5. Treatment with zanubrutinib should be discontinued upon the occurrence of any of the following: 5.1. progression of disease according to iwCLL response assessment criteria 5.2. unacceptable toxicity. 6. Zanubrutinib should only be prescribed by a clinician with expertise and experience in the treatment of CLL and monitoring of therapy. 7. Zanubrutinib should provide cost savings for drug programs relative to the cost of treatment with either ibrutinib or acalabrutinib for the treatment of adult patients with CLL. Guidance on sequencing: pERC agreed with the clinical expert consulted by CADTH that selection of a BTK inhibitor as a treatment option will be influenced by differences in patient populations and preferences such as dosing schedule duration of therapy, side effect profile, and concomitant drug interactions, pERC also noted the lack of definitive clinical evidence and rationale that favour BTK inhibitor option over another, and thus selection of the BTK inhibitor, would be for the treating clinician to determine in agreement with the patient. pERC agreed with the clinical expert consulted by CADTH that patients who have high-risk features or could not receive IV therapy should be able to obtain a BTK inhibitor. Although the clinical expert noted that patients who are doing well on current treatment (e.g., with ibrutinib or acalabrutinib be aligned			Patients must have a good ECOG performance status.
3.2. prolymphocytic leukemia or Richter's transformation. 4. Renewal of zanubrutinib should be based on the following assessments: 4.1. Blood work and physical examination should be performed every 1 to 3 months at initiation then can be performed less frequently (i.e., 3 to 6 months) at the discretion of the treating physician. 5. Treatment with zanubrutinib should be discontinued upon the occurrence of any of the following: 5.1. progression of disease according to iwCLL response assessment criteria 5.2. unacceptable toxicity. 6. Zanubrutinib should only be prescribed by a clinician with expertise and experience in the treatment of CLL and monitoring of therapy. 7. Zanubrutinib should provide cost savings for drug programs relative to the cost of treatment with either ibrutinib or acalabrutinib for the treatment of adult patients with CLL. Guidance on sequencing: pERC agreed with the clinical expert consulted by CADTH that selection of a BTK inhibitor as a treatment option will be influenced by differences in patient populations and preferences such as dosing schedule and duration of therapy, side effect profile, and concomitant drug interactions, pERC also noted the lack of definitive clinical evidence and rationale that favours TRi inhibitor option over another, and thus selection of the BTK inhibitor, would be for the treating clinician to determine in agreement with the patient. pERC agreed with the clinical expert consulted by CADTH that patients who have high-risk features or could not receive IV therapy should be able to obtain a BTK inhibitor. Although the clinical expert consulted by CADTH noted there should not be too many restrictions on the use of zanubrutinib because the drug may have cortain benefits over the earlier BTK inhibitors, PERC recommended that reimbursement criteria for zanubrutinib be aligned with the eligibility criteria outlined under initiation. The clinical expert noted that patients who are doing well on current treatment (e.g., with ibrutinib or acalabrutinib) without di			
4.1. Blood work and physical examination should be performed every 1 to 3 months at initiation then can be performed less frequently (i.e., 3 to 6 months) at the discretion of the treating physician. 5. Treatment with zanubrutinib should be discontinued upon the occurrence of any of the following: 5.1. progression of disease according to iwCLL response assessment criteria 5.2. unacceptable toxicity. 6. Zanubrutinib should only be prescribed by a clinician with expertise and experience in the treatment of CLL and monitoring of therapy. 7. Zanubrutinib should provide cost savings for drup programs relative to the cost of treatment with either ibrutinib or acalabrutinib for the treatment of adult patients with CLL. Guidance on sequencing: pERC agreed with the clinical expert consulted by CADTH that selection of a BTK inhibitor as a treatment option will be influenced by differences in patient populations and preferences such as dosing schedule and duration of therapy, side effect profile, and concomitant drug interactions, pERC also noted the lack of definitive clinical evidence and rationale that favours 1 BTK inhibitor option over another, and thus selection of the BTK inhibitor option over another, and thus selection of the BTK inhibitor option over another, and thus selection of the BTK inhibitor option over another, and thus selection of the BTK inhibitor option over another, and thus selection of the BTK inhibitor and perfect of the service of the BTK inhibitor option over another, and thus selection of the BTK inhibitor. pERC agreed with the clinical expert consulted by CADTH noted there should not be too many restrictions on the use of zanubrutinib beauses the drug may have certain benefits over the earlier BTK inhibitors, pERC recommended that reimbursement criteria for zanubrutinib beauses the drug may have certain benefits over the earlier BTK inhibitors, pERC recommended that reimbursement criteria for zanubrutinib beauses the drug may have certain benefits over the earlier BTK inhibitors pERC re			
of any of the following: 5.1. progression of disease according to iwCLL response assessment criteria 5.2. unacceptable toxicity. 6. Zanubrutinib should only be prescribed by a clinician with expertise and experience in the treatment of CLL and monitoring of therapy. 7. Zanubrutinib should provide cost savings for drug programs relative to the cost of treatment with either ibrutinib or acalabrutinib for the treatment of adult patients with CLL. Guidance on sequencing: pERC agreed with the clinical expert consulted by CADTH that selection of a BTK inhibitor as a treatment option will be influenced by differences in patient populations and preferences such as dosing schedule and duration of therapy, side effect profile, and concomitant drug interations, pERC also noted the lack of definitive clinical evidence and rationale that favours 1 BTK inhibitor over another, and thus selection of the BTK inhibitor, would be for the treating clinician to determine in agreement with the patient. pERC agreed with the clinical expert consulted by CADTH that patients who have high-risk features or could not receive IV therapy should be able to obtain a BTK inhibitor. Although the clinical expert consulted by CADTH noted there should not be too many restrictions on the use of zanubrutinib because the drug may have certain benefits over the earlier BTK inhibitors, pERC recommended that reimbursement criteria for zanubrutinib be aligned with the eligibility criteria outlined under initiation. The clinical expert noted that patients who are doing well on current treatment (e.g., with ibrutinib or acalabrutinib) without disease progression should not be switched. Venetoclax (Venclexta) in combination with Obinutuzumab (VEN-OBI) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible as indicated by either a Cumulative Illness Rating Scale (CIRS) score greater than indicated by either a Cumulative Illness Rating Scale (CIRS) score greater than			4.1. Blood work and physical examination should be performed every 1 to 3 months at initiation then can be performed less frequently (i.e., 3
experience in the treatment of CLL and monitoring of therapy. 7. Zanubrutinib should provide cost savings for drug programs relative to the cost of treatment with either ibrutinib or acalabrutinib for the treatment of adult patients with CLL. Guidance on sequencing: pERC agreed with the clinical expert consulted by CADTH that selection of a BTK inhibitor as a treatment option will be influenced by differences in patient populations and preferences such as dosing schedule and duration of therapy, side effect profile, and concomitant drug interactions. pERC also noted the lack of definitive clinical evidence and rationale that favours 1 BTK inhibitor option over another, and thus selection of the BTK inhibitor, would be for the treating clinician to determine in agreement with the patient. pERC agreed with the clinical expert consulted by CADTH that patients who have high-risk features or could not receive IV therapy should be able to obtain a BTK inhibitor. Although the clinical expert consulted by CADTH noted there should not be too many restrictions on the use of zanubrutinib because the drug may have certain benefits over the earlier BTK inhibitors, pERC recommended that reimbursement criteria for zanubrutinib be aligned with the eligibility criteria outlined under initiation. The clinical expert noted that patients who are doing well on current treatment (e.g., with ibrutinib or acalabrutinib) without disease progression should not be switched. Venetoclax (Venclexta) in combination with Obinutuzumab (VEN-OBI) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible if the following condition is met: • Cost-effectiveness improves to an acceptable level. Patients should have previously untreated CLL, be fludarabine ineligible as indicated by either a Cumulative Illiness Rating Scale (CIRS) score greater than			of any of the following: 5.1. progression of disease according to iwCLL response assessment criteria
cost of treatment with either ibrutinib or acalabrutinib for the treatment of adult patients with CLL. Guidance on sequencing: pERC agreed with the clinical expert consulted by CADTH that selection of a BTK inhibitor as a treatment option will be influenced by differences in patient populations and preferences such as dosing schedule and duration of therapy, side effect profile, and concomitant drug interactions. pERC also noted the lack of definitive clinical evidence and rational that favours 1 BTK inhibitor option over another, and thus selection of the BTK inhibitor, would be for the treating clinician to determine in agreement with the patient. pERC agreed with the clinical expert consulted by CADTH that patients who have high-risk features or could not receive IV therapy should be able to obtain a BTK inhibitor. Although the clinical expert consulted by CADTH noted there should not be too many restrictions on the use of zanubrutinib because the drug may have certain benefits over the earlier BTK inhibitors, pERC recommended that reimbursement criteria for zanubrutinib be aligned with the eligibility criteria outlined under initiation. The clinical expert noted that patients who are doing well on current treatment (e.g., with ibrutinib or acalabrutinib) without disease progression should not be switched. Venetoclax (Venclexta) in combination with Obinutuzumab (Venclexta) in critical expert consulted chronic lymphocytic leukemia (CLL) who are fludarabine ineligible if the following condition is met: • Cost-effectiveness improves to an acceptable level. Patients should have previously untreated CLL, be fludarabine ineligible as indicated by either a Cumulative Illness Rating Scale (CIRS) score greater than			
pERC agreed with the clinical expert consulted by CADTH that selection of a BTK inhibitor as a treatment option will be influenced by differences in patient populations and preferences such as dosing schedule and duration of therapy, side effect profile, and concomitant drug interactions. pERC also noted the lack of definitive clinical evidence and rationale that favours 1 BTK inhibitor option over another, and thus selection of the BTK inhibitor, would be for the treating clinician to determine in agreement with the patient. pERC agreed with the clinical expert consulted by CADTH that patients who have high-risk features or could not receive IV therapy should be able to obtain a BTK inhibitor. Although the clinical expert consulted by CADTH noted there should not be too many restrictions on the use of zanubrutinib because the drug may have certain benefits over the earlier BTK inhibitors, pERC recommended that reimbursement criteria for zanubrutinib be aligned with the eligibility criteria outlined under initiation. The clinical expert noted that patients who are doing well on current treatment (e.g., with ibrutinib or acalabrutinib) without disease progression should not be switched. Venetoclax (Venclexta) in combination with Obinutuzumab (VEN-OBI) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible if the following condition is met: • Cost-effectiveness improves to an acceptable level. Patients should have previously untreated CLL, be fludarabine ineligible as indicated by either a Cumulative Illness Rating Scale (CIRS) score greater than			cost of treatment with either ibrutinib or acalabrutinib for the treatment of
BTK inhibitor as a treatment option will be influenced by differences in patient populations and preferences such as dosing schedule and duration of therapy, side effect profile, and concomitant drug interactions. pERC also noted the lack of definitive clinical evidence and rationale that favours 1 BTK inhibitor option over another, and thus selection of the BTK inhibitor, would be for the treating clinician to determine in agreement with the patient. pERC agreed with the clinical expert consulted by CADTH that patients who have high-risk features or could not receive IV therapy should be able to obtain a BTK inhibitor. Although the clinical expert consulted by CADTH noted there should not be too many restrictions on the use of zanubrutinib because the drug may have certain benefits over the earlier BTK inhibitors, pERC recommended that reimbursement criteria for zanubrutinib be aligned with the eligibility criteria outlined under initiation. The clinical expert noted that patients who are doing well on current treatment (e.g., with ibrutinib or acalabrutinib) without disease progression should not be switched. Venetoclax (Venclexta) in combination with Obinutuzumab (Gazyva) PERC conditionally recommends reimbursement of venetoclax (Venclexta) in combination with obinutuzumab (VEN-OBI) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible if the following condition is met: • Cost-effectiveness improves to an acceptable level. Patients should have previously untreated CLL, be fludarabine ineligible as indicated by either a Cumulative Illness Rating Scale (CIRS) score greater than			Guidance on sequencing:
have high-risk features or could not receive IV therapy should be able to obtain a BTK inhibitor. Although the clinical expert consulted by CADTH noted there should not be too many restrictions on the use of zanubrutinib because the drug may have certain benefits over the earlier BTK inhibitors, pERC recommended that reimbursement criteria for zanubrutinib be aligned with the eligibility criteria outlined under initiation. The clinical expert noted that patients who are doing well on current treatment (e.g., with ibrutinib or acalabrutinib) without disease progression should not be switched. Venetoclax (Venclexta) in combination with Obinutuzumab (Gazyva) PERC conditionally recommends reimbursement of venetoclax (Venclexta) in combination with obinutuzumab (VEN-OBI) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible if the following condition is met: Cost-effectiveness improves to an acceptable level. Patients should have previously untreated CLL, be fludarabine ineligible as indicated by either a Cumulative Illness Rating Scale (CIRS) score greater than			BTK inhibitor as a treatment option will be influenced by differences in patient populations and preferences such as dosing schedule and duration of therapy, side effect profile, and concomitant drug interactions. pERC also noted the lack of definitive clinical evidence and rationale that favours 1 BTK inhibitor option over another, and thus selection of the BTK inhibitor, would be for the treating
many restrictions on the use of zanubrutinib because the drug may have certain benefits over the earlier BTK inhibitors, pERC recommended that reimbursement criteria for zanubrutinib be aligned with the eligibility criteria outlined under initiation. The clinical expert noted that patients who are doing well on current treatment (e.g., with ibrutinib or acalabrutinib) without disease progression should not be switched. Venetoclax (Venclexta) in combination with Obinutuzumab (Gazyva) PERC conditionally recommends reimbursement of venetoclax (Venclexta) in combination with obinutuzumab (VEN-OBI) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible if the following condition is met: • Cost-effectiveness improves to an acceptable level. Patients should have previously untreated CLL, be fludarabine ineligible as indicated by either a Cumulative Illness Rating Scale (CIRS) score greater than			have high-risk features or could not receive IV therapy should be able to obtain
(e.g., with ibrutinib or acalabrutinib) without disease progression should not be switched. Venetoclax (Venclexta) in combination with Obinutuzumab (Gazyva) PERC conditionally recommends reimbursement of venetoclax (Venclexta) in combination with obinutuzumab (VEN-OBI) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible if the following condition is met: Cost-effectiveness improves to an acceptable level. Patients should have previously untreated CLL, be fludarabine ineligible as indicated by either a Cumulative Illness Rating Scale (CIRS) score greater than			many restrictions on the use of zanubrutinib because the drug may have certain benefits over the earlier BTK inhibitors, pERC recommended that reimbursement criteria for zanubrutinib be aligned with the eligibility criteria
in combination with Obinutuzumab (Gazyva) combination with obinutuzumab (VEN-OBI) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible if the following condition is met: Cost-effectiveness improves to an acceptable level. Patients should have previously untreated CLL, be fludarabine ineligible as indicated by either a Cumulative Illness Rating Scale (CIRS) score greater than			(e.g., with ibrutinib or acalabrutinib) without disease progression should not be
Patients should have previously untreated CLL, be fludarabine ineligible as indicated by either a Cumulative Illness Rating Scale (CIRS) score greater than	in combination with	November 17, 2020	combination with obinutuzumab (VEN-OBI) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are
indicated by either a Cumulative Illness Rating Scale (CIRS) score greater than			Cost-effectiveness improves to an acceptable level.
6 or a creatinine clearance (CrCl) less than 70 mL/min, require treatment			Patients should have previously untreated CLL, be fludarabine ineligible as indicated by either a Cumulative Illness Rating Scale (CIRS) score greater than 6 or a creatinine clearance (CrCl) less than 70 mL/min, require treatment



	according to the International Workshop on Chronic Lymphoma Leukemia criteria, and have good performance status.
	Treatment should be given for a total of 12 months as a finite treatment: for six 28-day cycles in combination with obinutuzumab (OBI) followed by 6 months of venetoclax (VEN) as a single agent.
November 3, 2016	pERC recommends reimbursement of ibrutinib (Imbruvica) as an option for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) for whom fludarabine-based treatment is considered inappropriate, conditional on the cost-effectiveness being improved to an acceptable level. Treatment should be for patients with a good performance status and until disease progression or unacceptable toxicity.
November 17, 2020	pERC conditionally recommends reimbursement of acalabrutinib as monotherapy in adult patients with relapsed or refractory CLL who have received at least 1 prior therapy, if the following condition is met: Cost-effectiveness being improved to an acceptable level.
	Eligible patients must have received at least 1 prior systemic therapy, have active disease according to 1 or more of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2008 criteria, and good performance status. Treatment with acalabrutinib should be continued until disease progression or unacceptable toxicity.
May 31, 2019	pERC conditionally recommends reimbursement of venetoclax (Venclexta) in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at least 1 prior therapy, irrespective of their 17p deletion status, only if the following condition is met: • Cost-effectiveness being improved to an acceptable level.
	Patients should have a good performance status and treatment should be continued until disease progression or unacceptable toxicity up to a maximum of 2 years, whichever comes first.
	Guidance on sequencing:
	pERC concluded that the optimal sequencing of venetoclax plus rituximab and other therapies, such as B-cell receptor inhibitors, in relapsed CLL is currently unknown, as there is insufficient evidence to inform this clinical situation. However, pERC recognized that provinces will need to address this issue upon implementation of reimbursement of venetoclax plus rituximab, and noted that a national approach to developing evidence-based clinical practice guidelines addressing the sequencing of treatments would be of value.
March 2, 2018	pERC conditionally recommends the reimbursement of venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL) who have received at least 1 prior therapy and who have failed a B-cell receptor inhibitor (BCRi) only if the following condition is met: • An improvement of cost-effectiveness in the form of a substantial price reduction until more robust clinical data are made available for a future
	November 17, 2020 May 31, 2019



Idelalisib (Zydelig) August 18, 2015	pERC recommends funding idelalisib (Zydelig), conditional on cost- effectiveness being improved to an acceptable level, when used in combination with rituximab for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL). Treatment should continue until unacceptable toxicity or disease progression.
---------------------------------------	---

BTK = Bruton tyrosine kinase; CLL = chronic lymphocytic leukemia; CNS = central nervous system; C+O = chlorambucil plus obinutuzumab; del(17p) = deletion of 17p; ECOG = Eastern Cooperative Oncology Group; I+V = ibrutinib plus venetoclax; iwCLL = International Workshop on Chronic Lymphocytic Leukemia.



Table 2: CADTH Implementation Advice Panels on Chronic Lymphocytic Leukemia

Date of publication	Implementation Advice
May 2021	The panel advises that both ACA and IBR should be reimbursed in the same manner, with decisions concerning initiation of therapy being individualized to patients, balancing considerations around patient characteristics with the total cost of care.
	 The panel advises that: Contingent on affordability challenges being addressed, options should remain available between IBR, ACA, and VEN-OBI in the first-line setting for all patients with CLL who are not eligible for fludarabine-based therapy. If the provinces cannot afford BTKi for their full indication, then they should be prioritized in patients with high-risk factors. Decisions concerning initiation of therapy should be individualized to patients balancing considerations around patient characteristics with the total cost of care.
	The panel advises that re-treatment with a VEN-based regimen should be available for patients with CLL who relapse, unless relapse occurs while receiving, or within 12 months of completing, a VEN-based regimen.
	 The panel advises that: Idelalisib should not be available following disease progression on ACA or other BTKi. Idelalisib should only be available on a case-by-case basis following intolerance and/or relapse after previous lines of therapy due to its poor tolerability and safety concerns relative to BTKi.
	 The panel advises that: Patients who are refractory to a BTKi in the first-line setting should next be treated with a VEN-based regimen. Patients who are intolerant, but not refractory, to a BTKi in the first-line setting may be treated with another BTKi or a VEN-based regimen.
	 The panel advises that: Patients who experience a shorter duration of remission (less than 12 months) following treatment with a VEN-based regimen may be offered next-line therapy with a BTKi. Patients who experience a longer duration of remission (12 months or more) following treatment with a VEN-based regimen may be offered next-line therapy with either a VEN-based regimen or a BTKi.
	The panel advises that: • Options should remain available for IBR, ACA, and a VEN-based regimen as next-line therapy for CLL patients following chemoimmunotherapy.
	Sequencing decisions should be individualized to each patient, balancing considerations around patient characteristics with the total cost of care.


ACA = acalabrutinib; BTKi = Bruton's tyrosine kinase inhibitor; CLL = chronic lymphocytic leukemia; IBR = ibrutinib; VEN = venetoclax.



Provisional Funding Algorithm

Figure 1: Provisional Funding Algorithm Diagram for Chronic Lymphocytic Leukemia

Alt text: First-line and relapsed or refractory treatment funding options for patients with chronic lymphocytic leukemia who have low or intermediate risk as well as high or very-high risk CLL.



Including del(17p) alteration, TP53 mutation and unmutated IGHV

Legend

Therapy funded across most Therapy under review for funding jurisdictions (pCPA or province/cancer agency)

BR = bendamustine-rituximab; Clb = chlorambucil; CVP = cyclophosphamide-vincristine-prednisone; FCR = fludarabinecyclophosphamide-rituximab; FR = fludarabine-rituximab; Obi = obinutuzumab; R = rituximab.

b The dosing schedule for VEN-OBI is for a fixed duration of 48 weeks.

Chromosomer is followed by ibrutinib 420 mg plus venetoclax 400 mg daily for twee 28day cycles, followed by ibrutinib 420 mg plus venetoclax 400 mg daily for twelve 28-day cycles. Venetoclax should be initiated at cycle 4 with dose ramp-up over 5 weeks. If patients have a durable response to first line ibrutinib-venetoclax (i.e., at least 1 years DOR) then retreatment with I+V

d Patients treated with ibrutinib-venetoclax as first line treatment should not be retreated with ibrutinib in the relapsed or refractory setting.

eldelalisib-rituximab available only in cases of intolerance of a BTKi or for bridging to cellular therapy.

Rituximab-containing therapy may be offered at time of relapse contingent on a progression-free interval of at least six months from prior anti-CD20 therapy or if no prior anti-CD20 therapy.

Rituximab-containing therapy may be offered at time of relapse contingent on a progression-free interval of at least six months from prior anti-CD20 therapy or if no prior anti-CD20 therapy.

h Venetoclax monotherapy only funded after failure of a BTKi



Description of the Provisional Funding Algorithm

First-Line

Low or intermediate risk

The first line options include flurdarabine-cyclophosphamide-rituximab (FCR), chemoimmunotherapy, venetoclax-obinutuzumab.or ibrutinib-venetoclax. Ibrutinib-venetoclax are under review for funding.

High or very-high risk CLL.

For patients with high or very high risk CLL which include del (17p) alteration, TP53 mutation and unmutated IGHV, their first line options include venetoclax-obinutuzumab, ibrutinib-venetoclax, acalabrutinib, ibrutinib and zanubrutinib. Both ibrutinib-venetoclax and Zanubrutinib are under review for funding. Note that venetoclax-obinutuzumab treatment is for a fixed duration of 48 weeks. Ibrutinib-venetoclax is given as a fixed duration, as a single drug at a dose of 420mg once daily for three 28-day cycles, followed by ibrutinib 420mg plus venetoclax 400mg daily for twelve 28-day cycles. Venetoclax should be initiated at cycle 4 with dose ramp-up ove 5 weeks. If patients have a durable response to first line ibrutinib-venetoclax (i.e., at least 1 year DOR) then retreatment with ibrutinib-venetoclax would be considered.

Relapsed or Refractory

Low or intermediate risk

For patients whose CLL is refractory to first-line therapies including FCR, chemoimmunotherapy or venetoclax-obinutuzumab, their subsequent options include acalabrutinib, ibrutinib, zanubrutinib, idelalisib with rituximab or venetoclax with or without rituximab.

For patients who have received ibrutinib-venetolax as first line treatment, they should not be retreated with ibrubinib in the relapsed or refractory setting.

Idelalisib-rituxumab would be available only in cases of intolerance of a BTKi or for bridging to cellular therapy.

Venetoclax retreatment is allowed at the time of relapse if the progression-free interval was at least 12 months after completion of previous therapy. Rituxumab-containing therapy may be offered at time of relapse contingent on a progression-free interval of at least six months from prior anti-CD20 therapy or there has been no prior anti-CD20 therapy.

For patients who have received ibrutinib-venetoclax in the first line setting, they may be retreated with the same options (acalabrutinib, ibrutinib, zanubrutinib, idelalisib with rituximab or venetoclax with or without rituximab) as well as ibrutinib-venetoclax if the disease free interval is 1 year or greater. If the disease free interval is less than 1 year, other alternate drug classes would be considered.

High or very-high risk CLL

For patients in the high or very-high risk CLL setting, the relapsed or refractory treatment funded options include acalabrutinib, ibrutinib, zanubrutinib or ibrutinib-venetoclax if the disease free interval is 1 year or greater.



If the disease free interval is less than 1 year, the relapsed or refractory treatment funded options include idelalisib with rituximab, ritixumab or other single agent chemotherapy.